Avantor stock had its Relative Strength (RS) Rating upgraded from 78 to 84 Tuesday amid positive Q2 earnings results.
IBD's proprietary rating measures share price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
History reveals that the market's biggest winners typically have an 80 or higher RS Rating as they launch their biggest price moves.
Hone Your Stock-Picking Skills By Focusing On These Factors
Is Avantor Stock A Buy?
Avantor stock is within a buying range after moving past a 26.16 buy point in a consolidation. Once a stock moves 5% or higher beyond the original entry, it's considered extended and out of buy range.
Although Q2 earnings and sales growth came in at -11% and -2%, respectively, in the latest report, that marked acceleration for both earnings-per-share and sales and beating analysts' estimates.
Avantor stock earns the No. 7 rank among its peers in the Medical-Research Equipment/Services industry group. Medpace Holdings, Myriad Genetics and Icon PLC are among the top 5 highly rated stocks within the group.
